<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:hpo ids='HP_0001297'>Stroke</z:hpo> patients often experience a significant temporal delay between the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and the time to initiation of therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, there is a need for neuroprotectants with a long therapeutic window of opportunity </plain></SENT>
<SENT sid="2" pm="."><plain>The efficacy of a potent, central <z:mp ids='MP_0008912'>nervous</z:mp> system-penetrating calpain inhibitor (MDL 28,170) was evaluated in a temporary model of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> to determine the window of opportunity for intracellular protease inhibition </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: An ex vivo brain protease inhibition assay established pharmacodynamic dosing parameters for MDL 28,170 </plain></SENT>
<SENT sid="4" pm="."><plain>Middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion was accomplished by advancing a monofilament through the internal carotid artery to the origin of the <z:chebi fb="70" ids="34342">MCA</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Postmortem <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were determined by quantitative image analysis of triphenyltetrazolium-stained brain sections </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Maximal inhibition of brain protease activity was observed 30 minutes after injection of MDL 28,170 with an estimated pharmacodynamic half-life of 2 hours </plain></SENT>
<SENT sid="7" pm="."><plain>MDL 28,170 caused a dose-dependent reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume when administered 30 minutes after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="8" pm="."><plain>A window of opportunity study was conducted to determine the maximal delay between the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and the initiation of efficacious therapy </plain></SENT>
<SENT sid="9" pm="."><plain>MDL 28,170 reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume when therapy was delayed for 0.5, 3, 4, and 6 hours after the initiation of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>The protective effect of MDL 28,170 was lost after an 8-hour delay </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: These data indicate that the therapeutic window of opportunity for calpain inhibition is at least 6 hours in a reversible focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model </plain></SENT>
<SENT sid="12" pm="."><plain>This protection is observed despite the lethal hypoxic and excitotoxic challenge, suggesting that calpain activation may be an obligatory, downstream event in the ischemic cell <z:hpo ids='HP_0011420'>death</z:hpo> cascade </plain></SENT>
</text></document>